Free Trial
NASDAQ:SGHT

Sight Sciences Q1 2025 Earnings Report

Sight Sciences logo
$3.09 -0.13 (-4.04%)
Closing price 04/28/2025 04:00 PM Eastern
Extended Trading
$3.09 0.00 (0.00%)
As of 04/28/2025 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sight Sciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.29
Beat/Miss
N/A
One Year Ago EPS
N/A

Sight Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$16.51 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sight Sciences Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Thursday, May 1, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Sight Sciences Earnings Headlines

Sight Sciences appoints new board member
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Sight Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sight Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sight Sciences and other key companies, straight to your email.

About Sight Sciences

Sight Sciences (NASDAQ:SGHT), an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

View Sight Sciences Profile

More Earnings Resources from MarketBeat